Numab Therapeutics AG announced that Intarcia Therapeutics Inc has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders. Numab discovered ND016 on behalf of Intarcia under a previous research and option agreement.
Under the present exclusive license agreement, Intarcia receives worldwide rights to develop and commercialize ND016 in exchange for license payments of up to CHF 70 million and up to double digit tiered royalties on net sales.
ND016 is a next generation tri-specific antibody fragment being developed for the treatment of autoimmune disorders. It simultaneously blocks the two pro-inflammatory cytokines, interleukin-17A, and tumor necrosis factor-alpha, each with outstanding potency.
The monovalent tri-specific molecule that additionally binds to serum albumin, is designed to support convenient dosing schemes, to achieve unmet activity in inflamed tissues, and to avoid the adverse effects observed with first generation bivalent formats.
Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immunooncology and immunology, and has partnerships with Intarcia Therapeutics, Ono Pharmaceutical, Kaken Pharmaceutical, and Tillotts Pharma.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment and prevention outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies.